A systematic review concluded that while genomic classifier (GC) tests could affect risk classifications or treatment choices for patients with localized prostate cancer (PCa), more research is ...

A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer but studies evaluating these tests vary ...

TAMPA, Fla. (Jan. 24, 2025) — A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris ...

Genomic tests give us a clearer picture of how aggressive prostate cancer might be. While these tests show promise, we need more well-designed studies to see exactly how they can improve treatment ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Opens in a new tab or window Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer ...

For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs ... after GPS testing were seen. "Although GC tests do not consistently influence risk classification ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs ...